- Home
- REX vs GENB Comparison
REX vs GENB Comparison
Compare REX & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REX | GENB |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 1994 | 2026 |
Fundamental Metrics
Financial Performance| Metric | REX | GENB |
|---|---|---|
| Price | $39.95 | $12.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 211.6K | ★ 943.9K |
| Earning Date | 12-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $650,487,000.00 | N/A |
| Revenue This Year | $18.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.27 | ★ N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $31.00 | $11.00 |
| 52 Week High | $53.36 | $22.67 |
Technical Indicators
Market Signals| Indicator | REX | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 40.06 |
| Support Level | $39.04 | $11.82 |
| Resistance Level | $44.82 | $13.96 |
| Average True Range (ATR) | 1.49 | 0.82 |
| MACD | -0.32 | -0.04 |
| Stochastic Oscillator | 2.65 | 29.19 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.